A patent for genome editing technology by a South Korean biotechnology company has been rejected for a lack of clarity, novelty, and inventiveness, but the Australian Patent Office has given the company two months to try again.
BMW Australia plans to challenge the NSW Supreme Court’s power to create a common fund order spanning six class actions brought against major players in the automotive industry over defective and dangerous Takata air bags.
The Australian Securities and Investments Commission failed to establish any grounds for permanently banning an ANZ financial adviser from the industry, a tribunal said in setting aside the decision Tuesday.
Vocational trainer Empower Institute engaged in unconscionable conduct by “duping” disadvantaged consumers into enrolling in courses they couldn’t afford with the promise of free laptops and cash, a judge ruled Wednesday.
The Full Federal Court has overturned a win for the consumer regulator in a case against Sydney-based Unique International College, ruling that the vocational trainer’s practices for marketing and enrolling students in its diploma courses did not amount to unconscionable conduct.
A judge has agreed to sign off on an order in a massive class action against Westpac that could give 25 percent of any recovery to the litigation funder underwriting the case, on the condition that the funder accept a rate reflecting the net, not the gross, sum.
Bega has admitted to allegations by Kraft that it distributed its peanut butter in boxes with the Kraft logo on the outside, but says it was allowed to under a license agreement.
The deputy chairman of the Australian Securities and Investments Commission, Peter Kell, has resigned just five months into a yearlong extension of his contract with the corporate watchdog.
MyBudget has successfully fought off a class action brought by consumers who claimed the budget management firm violated consumer law by holding onto interest earned on their personal budgeting accounts.
Generic drug company Alphapharm has lost a bid for documents it claimed would show Sanofi-Aventis suspected as early as 2015 that patents for one of its injector pens may be invalid.
For information on rights and reprints, contact subscriptions@lawyerly.com.au
